Skip to main content

Biostage Files for FDA Orphan Drug Designation for Cellspan™ Esophageal Implant

Biostage, Inc. (Nasdaq: BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced it has submitted an application with the U.S. Food and Drug Administration seeking orphan drug designation for its Cellspan Esophageal Implants.
http://www.stockhouse.com/news/press-releases/2016/06/29/biostage-files-for-fda-orphan-drug-designation-for-cellspan-esophageal-implant

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2022 Esophageal Cancer Education Foundation- by domino